Skip to main content

Navigation group

Type at least 3 characters
130 articles

Articles

Original Research

Published on 23 Oct 2023

Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason

in Therapy in Gastroenterology

  • Giammarco Mocci
  • Arianna Cingolani
  • Giorgia Orrù
  • Carla Felice
  • Francesca Maria Onidi
  • Gianmarco Lombardi
  • Davide Checchin
  • Raffaele Colucci
  • Laurino Grossi
  • Antonio Ferronato
Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason
Frontiers in Gastroenterology
doi 10.3389/fgstr.2023.1218228
  • 834 views
  • 1 citation

Original Research

Published on 14 Sep 2023

Efficacy and safety of Lacticaseibacillus rhamnosus R0011 and Lactobacillus helveticus R0052 as an adjuvant for Helicobacter pylori eradication: a double-blind, randomized, placebo-controlled study

in Gastrointestinal Infection

  • Anya Kiattiweerasak
  • Natsuda Aumpan
  • Soonthorn Chonprasertsuk
  • Bubpha Pornthisarn
  • Sith Siramolpiwat
  • Patommatat Bhanthumkomol
  • Pongjarat Nunanan
  • Navapan Issariyakulkarn
  • Varocha Mahachai
  • Yoshio Yamaoka
Efficacy and safety of Lacticaseibacillus rhamnosus R0011 and Lactobacillus helveticus R0052 as an adjuvant for Helicobacter pylori eradication: a double-blind, randomized, placebo-controlled study
Frontiers in Gastroenterology
doi 10.3389/fgstr.2023.1245993
  • 2,435 views